14.01.2013 Views

Visit our Expo - Redox and Inflammation signaling 2012

Visit our Expo - Redox and Inflammation signaling 2012

Visit our Expo - Redox and Inflammation signaling 2012

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Session XIV : Transcriptional <strong>and</strong> translational control Poster XIV, 78<br />

NFAT <strong>and</strong> bone disease: a possible “decoy” therapeutic approach<br />

Margherita Zennaro, Elisabetta Lambertini, Roberto Gambari, Letizia Penolazzi <strong>and</strong><br />

Roberta Piva.<br />

Department of Biochemistry <strong>and</strong> Molecular Biology, University of Ferrara, Italy. Email:<br />

piv@unife.it<br />

Bone is a dynamic tissue, under constant remodelling all life long. This process results from<br />

the balance between the activity of osteoblasts (OBs) <strong>and</strong> osteoclasts (OCs), that deposit <strong>and</strong><br />

resorb bone respectively. Any modification of this delicated equilibrium can affect bone<br />

integrity, leading to patologies such as osteopenic disorders or osteopetrosis. A central role in<br />

the control of OCs functions <strong>and</strong> in some OBs activities too, was recently described for<br />

Nuclear Factor of Activated T-cells (NFAT) c1. In this study, we suggest a possible<br />

involvment of NFATc1 in the transcriptional regulation of human estrogen receptor alpha<br />

(ER) gene in both kind of cells. It is well known that estrogen influences OBs <strong>and</strong> OCs<br />

activities, playing a fundamental role in protection of bone mass, as indicated, for example, by<br />

association of osteoporosis <strong>and</strong> menopause.<br />

We previously demonstrated that a specific oligonucleotide (RA4-3’) used as decoy molecule<br />

can increase ER expression in bone cells, by interfering with the activity of an unidentified<br />

negative transcription factor. Interestingly, RA4-3’ sequence contains a putative binding site<br />

(TGAAAA) for NFAT that is the aim of these investigations. First of all we detected a high<br />

level of NFATc1 expression in OCs <strong>and</strong> in SaOS-2 osteoblastic cells, treated with PMA <strong>and</strong><br />

ionomycin. We then verified the specificities of the interaction between NFAT protein <strong>and</strong><br />

<strong>our</strong> sequence, by using cross competition in electrophoretic mobility shift assay. Preliminary<br />

results indicat that a specific interaction between NFAT <strong>and</strong> <strong>our</strong> sequence occurs, probably<br />

mediated by some NFAT co-transcription factors, such as AP-1. Next, we verified NFAT<br />

functionality in OCs <strong>and</strong> SaOS-2 through the transfection of pNFAT-TA luc cis-reporter<br />

vector, containing three t<strong>and</strong>em copies of the NFAT-consensus sequence upstream of the<br />

luciferase gene, in combination with RA4-3’. This caused a decrease of Luc activity, due to<br />

the recruitment of NFAT proteins by RA4-3’. In addition, we demonstrated that RA4-3’<br />

selectively induces apoptosis in OCs but not in OBs. In view of a possible therapeutic<br />

application of NFAT decoy, the role of NFAT in this issue was also investigated.<br />

- 581 -

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!